Comprehensive analysis of prognostic value and immune infiltration of CDK1 in lung cancer

Author:

Zhu Yunying1,Yu Qinhua2,Lei Chenshuang3,Qiu Liannv2

Affiliation:

1. Zhejiang Chinese Medical University

2. Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College)

3. Wenzhou Central Hospital

Abstract

Abstract Objective: Lung cancer is one of the common malignant tumors worldwide with poor prognosis. Cyclin dependent kinase 1 (CDK1) plays crucial roles in regulating of cell cycle transition and is mainly involved in the development and progression of various tumors, however, little is known about its function in lung cancer. Methods: The Cancer Genome Atlas (TCGA), Gene Expression Profiling Interactive Analysis (GEPIA), Clinical Proteomic Tumor Analysis Consortium (CPTAC) and Human Protein Atls (HPA) were used to evaluate the level of CDK1. Kaplan-Meier (K-M) Plotter, receiver operating characteristic (ROC) curve and Cox regression analyses were used to evaluate the value of CDK1 in lung cancer. Gene functional and pathways were assessed using Gene ontology (GO) analysis and gene set enrichment analysis (GSEA) The immune infiltration analysis was investigated basing on Single-sample gene set enrichment analysis (ssGSEA) . Results: The expression of CDK1 was significantly upregulatedin lung cancer patients, especially in those with advanced stage. Elevated CDK1 was associated with advanced clinical stage, shorter overall survival (OS) and disease specific survival (DSS) in lung cancer. Moreover, the functions of CDK1 were primarily related to cell cycle regulation and immune response. Most interestingly, the expression of CDK1 was associated with the infiltration immune cells and immune checkpoints. Conclusions: Our results revealed that CDK1 may be a diagnostic and prognostic biomarker in lung cancer. CDK1 plays a role in tumor immune evasion and may provide a potential therapeutic target to overcome immunity resistance in lung cancer.

Publisher

Research Square Platform LLC

Reference45 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung H;CA Cancer J Clin,2021

2. Cancer statistics, 2020;Siegel RL;CA Cancer J Clin,2020

3. Nooreldeen R, Bach H. Current and Future Development in Lung Cancer Diagnosis.Int J Mol Sci. 2021;22(16).

4. Genetic Markers in Lung Cancer Diagnosis: A Review;Wadowska K;Int J Mol Sci,2020

5. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets;Kumar AR;Mol Biol Rep,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3